Inspire Medical Systems, Inc. (NYSE:INSP) Receives $81.26 Consensus PT from Analysts

Inspire Medical Systems, Inc. (NYSE:INSP) has received an average rating of “Hold” from the twenty-one ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $74.8333.

Several brokerages recently commented on INSP. Freedom Capital upgraded Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. Mizuho decreased their price target on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Bank of America cut Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price target for the company. in a report on Friday, May 22nd. Summit Redstone set a $39.00 price objective on shares of Inspire Medical Systems in a research note on Friday, May 22nd. Finally, Stifel Nicolaus dropped their price objective on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th.

Hedge Funds Weigh In On Inspire Medical Systems

A number of institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its stake in shares of Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after acquiring an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Inspire Medical Systems in the first quarter worth about $524,000. Goldman Sachs Group Inc. lifted its stake in shares of Inspire Medical Systems by 57.9% in the first quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after acquiring an additional 18,857 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Inspire Medical Systems by 3.8% in the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after acquiring an additional 577 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in Inspire Medical Systems in the second quarter valued at about $931,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Trading Down 2.8%

Shares of NYSE INSP opened at $49.38 on Friday. Inspire Medical Systems has a 12-month low of $38.91 and a 12-month high of $147.03. The company has a market cap of $1.42 billion, a P/E ratio of 11.00, a P/E/G ratio of 5.14 and a beta of 0.71. The stock has a fifty day moving average price of $45.24 and a 200 day moving average price of $57.35.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. During the same period last year, the company posted $0.10 earnings per share. The firm’s revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, sell-side analysts forecast that Inspire Medical Systems will post 0.93 EPS for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.